Towards imaging the immune state of cancer by PET: Targeting legumain with 11C-labeled P1-Asn peptidomimetics carrying a cyano-warhead
The legumain tracers [<sup>11</sup>C]1 and [<sup>11</sup>C]2, synthesized with high radiochemical purity and molar activity, accumulate in the legumain-positive CT26 tumor in vivo. However, the lack of competition by excess compound questions their specificity. Both tracers are rapidly metabolized in vivo, requiring structural modifications towards more stable tracers for further investigations.
Authors
- Richard D. Williams (ORCID: https://orcid.org/0000-0002-7710-2975)
- Linjing Mu (ORCID: https://orcid.org/0000-0001-5354-1546)
- Roger Schibli (ORCID: https://orcid.org/0000-0002-1537-3833)
- Claudia A. Castro Jaramillo
- Stefanie D. Krämer (ORCID: https://orcid.org/0000-0002-0426-4340)
- Lena A Bärtschi
- Severin Lustenberger
Institutions
- Queen's University Belfast (GB)
- ETH Zurich (CH)
- Queens University (BD)
Publication Details
- Journal
- Nuclear Medicine and Biology
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1016/j.nucmedbio.2024.108951
- Citations
- 4
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Krebsliga Schweiz